
Index

Note: boxed text is indicated by **boldened page numbers**, and Figures and Tables by *italic numbers*

- absolute risk difference (ARD) **17**,
229
- absolute risk reduction (ARR) **17, 18**
- acupuncture study **66, 86, 92**
- age-specific mortality rate
(ASMR) 219–20
- agreement between methods, Bland–
Altman plots **211, 212**
- agreement between observers 206–8
Cohen's kappa 207–8
weighted kappa 208
- agreement by chance 207, 214–15
- AIDS data **162, 163**
- anaemia in women (survey) **150–1, 152,**
153, 155, 156, 157, 158, 159, 160, 161,
165, 166–8, 169–70, 170–1,
172
- analysis of variance (ANOVA)
method 131
- APACHE scores **57, 58, 59**
- approximate relative risk 19, 20
- aspiration risk study **55, 56**
- aspirin study **110**
- association
and agreement 211
correlation coefficient as measure 151,
211
- attributable risk (AR) 229
worked example **230**
- average *see* mean
- baby weight-change study **280–1**
- balanced randomisation techniques
245–6
- bar charts 21–2, 42
clustered 22–3
- baseline adjustments 280–1
- Bayes' Theorem 51–7
formula 53
illustrative application **53**
- before-and-after studies 224–5, 247
- behavioural therapy trial **267**
- 'bell-shaped' distribution *see* Normal
distribution
- between-subject standard deviation 204,
213

- between-subject variance 213
- between-subject variation 39, 41
- bias, in cross-sectional studies 223
- bimodal distribution 30
- binary data 6, 14
 - comparing outcomes 16–19
 - labelling outcomes 16
 - regression analysis *see* logistic regression
 - sample size calculations 264, 265, 268–71
- binary diagnostic choice 207
- binary logistic regression 169
- Binomial distribution 64–5, 66
 - population parameters 65, 94
 - for comparing two groups 95, 114
 - probability distribution function 75
- birthweight surveys 69, **72**, 73, **74**, 82, 83, 90
- Bland–Altman plots **211**, 212
- blinding, clinical trials 10, 248
- blocked randomisation 245–6
- blood pressure 3, 8, 9, 11, 104
- Bonferroni correction 289
- box–whisker plot 36, 37
- Bradford Hill, Austin 243
- Bradford Hill criteria 237–8
- brain water content MRI study **162**, 164
- breast cancer study **250**
- breast self-examination trial **253–4**

- cannabis study 20, **20**, 21
- case–control studies 231–7
 - analysis by matching 235
 - confounding in 236
 - design 231–2
 - limitations 237
 - logistic regression used in 172
 - matched design 234–5
 - notation 232, 234
 - over-matching 236
 - paired data in 136–8
 - selection of controls 235–6
 - Simpson’s paradox 236
 - unmatched design 232–3
- case-referent studies *see* case–control studies
- categorical classifications, kappa statistic used 208
- categorical data 6–8, 6, 13–25
 - displaying 21–3
 - summarising 14–21
- categorical outcomes
 - comparison of two groups of paired observations 136–8
 - comparison of two independent groups 132–6
- causality, Bradford Hill criteria 237–8
- causality/causation
 - and association 237–8
 - and correlation 174
- censored observations (in survival analysis) 182, 184
 - absence in (example) trial **185**
 - causes 184
 - and Kaplan–Meier survival curve 186
- censored survival time 184
- Central Limit Theorem 84–5, 91
- central tendency 28
- chi-squared distribution, table(s) for 135, 136, 320
- chi-squared test(s) 126, 132
 - for association in $r \times c$ contingency table 134–6
 - for trend in $2 \times c$ table 136, 143
 - with Yates’ continuity correction 126, 132, 135, 136
- chlamydial infection studies **172**, **173**, 174, **224**
- cholesterol, change in **283**, 284
- chronic fatigue study **105**
- chronic obstructive pulmonary disease (COPD), physiotherapy trial **87–8**, **93**, 101
- cigarette smoking, effects 3, 17, 230
- clinical importance, distinguished from statistical significance 111, 288
- clinical trial 242
 - historical controls 244
 - subject withdrawals 271–2
 - see also* randomised controlled trial
- closed questions 221, **222**
- cluster randomised trials 252–3
- clustered bar chart 22–3
- coefficient of variation (CV) 203
- Cohen’s kappa 207–8
 - worked example **207–8**

- cohort studies 227–31
 - attributable risk 229
 - design 227–31
 - interpretation 230, 231
 - notation used 228
 - progress 228
 - relative risk ratio 227
 - size 231
 - slate-workers example **228, 229, 230**
- comparison of more than two groups 131
- comparison of two groups
 - independent groups
 - categorical outcomes 132–6
 - with continuous outcomes 125–31
 - paired observations
 - with categorical outcomes 136–8
 - with continuous outcomes 119–25
- confidence interval (CI)
 - clinical importance distinguished from statistical significance by using 111
 - for difference in means 93, 122, 123, 127, 128
 - for difference in proportions 93, 133, 144
 - for hazard ratio 192–3
 - for mean 89–91
 - for odds ratio 239
 - for proportion 91–2, 95, **95–6**
 - for rate 92
 - relationship to statistical significance 112
 - for relative risk 238–9
- confounding
 - in multiple regression 166–7
 - adjusting for differences 167–8
 - in observational studies 4–5, 236
- confounding factors 5, 218
- CONSORT statement 258
- contingency table(s) **15, 16**
 - chi-squared test for association in 134–6
- continuous data 6, 8
 - dichotomisation of 8, 175
 - displaying 34–9
 - probabilities for 68–9
 - regression analysis *see* linear regression
- sample size calculations 264, 265, 267
 - summarising 28–34
- continuous outcomes
 - comparison of two groups of paired observations 119–25
 - comparison of two independent groups 125–31
- contraceptive pill, deep vein thrombosis risk **18**
- control subjects/groups 10, **18**
 - lacking in before-and-after studies 225
- convenience samples 81–2, 223
- correlation 150, 151–6
 - and causation 174
 - compared with regression 150, 165–6
 - significance test 155–6
- correlation coefficient 151–3, 175–6
 - inappropriate use 153–5, 211
 - as measure of association 151, 211
- scatter plots showing different correlations 153
 - worked example **176**
- count data 6, 8, 14, 131
- Cox proportional hazards regression model 194–7
 - technical example **195**
 - worked example **195**
- Cronbach's alpha 209
 - calculation 213–14
- cross-over trials 119, 136, 251–2, 279
 - difficulties 252
- cross-sectional studies **172, 222–4**
 - compared with other observational study designs 224
 - sampling schemes 222–3
- cross-tabulated data **15, 16, 132**
- crude mortality rate (CMR) **15, 46, 47, 219**
- cumulative survival probability 186–7
 - plot against time (K-M curve) 187, 189
- data
 - display of 11
 - categorical data 21–3
 - continuous data 34–9
 - types 5–9

- 'data-dredging exercises' 289
- death rate(s) **15**, 46, 47, 193, 219–20
- degrees of freedom **33**, 139–40
 - omission from results 279
- design of study 4–5, 11
- diabetes trials **251**, **253**
- diagnostic tests 49–51, 60, 73
 - sensitivity 49–51
 - specificity 49–51
 - uses 49
- dichotomisation of continuous data 8, 175
- difference in means 93, 95, *114*
 - confidence interval for 93, 122, *123*, *127*, *128*
 - standard error for **87–8**, 95, 121, *123*, *127*, *128*
- difference in proportions 93, 95, *114*
 - confidence interval for 93, 133, 144
 - standard error for **88**, 95, 133, 144
- difference in rates
 - confidence interval for 93
 - standard error for 95
- discrete data 8, 131
 - probabilities for 64–7
- dispersion measures 28, 30–3
- distributions 63–77
 - bimodal 30
 - Binomial 64–5, 66, 75
 - Normal 69–73, *316–17*
 - Poisson 66–7, 75–6
 - skewed 38–9
- dot plots 34, 35, 83
- double-blind randomised trials 10, 248

- effect size 265–6
- endometrial cancer study **5**, 7, **30**, **33**, 39
- equivalence trials 249–50
- evidence-based medicine 2
- excess risk 229
- exchangeable error 213
- exploratory data analysis 288–90

- factorial design (randomised controlled trial) 247, 253–4
- false-negative error (Type II error) 109, *110*
- false-negative rate 51
- false-positive error (Type I error) 107, 109, *110*
- false-positive rate 51

- Fisher, R A 243
- Fisher's exact test 126, 134, 136, 141–2
- 'fishing expeditions' 288–9
- fluoridated water supplies study **4**
 - confounding variables in 4, 5
- follow-up studies *see* cohort studies
- forced expiratory volume (FEV₁)
 - measurements 176
 - repeatability 213
- forms, purpose 221
- frequency probability 46–8

- 'gold standard' 49, **55**, 60, 202
- grab samples 223
- graphical presentation 42

- hazard rate 193
- hazard ratio (HR) 190–3
 - calculation procedure 191–2
 - confidence interval for 192–3
 - meaning of term 191
 - worked example **191**
 - see also* relative risk
- 'healthy worker' effect (in observational studies) 224, 231
- heart disease diagnosis study **50**
- heart donor study **67**, **87**, **92**
- histograms 35–6, 36, 42, 68, 69, 86, *122*, *129*
 - choice of group interval 11
- historical controls 244
- hypertension 8, 49
- hypothesis testing 105–8

- incidence, meaning of term 219, 220
- independence of events/observations 56, 57
 - violation of 161
- independent groups of data/observations
 - comparison of two groups
 - for categorical outcomes 132–6
 - for continuous outcomes 125–31
 - see also* unpaired data
- independent two-sample *t*-test 125–8
- initial value, plotting change
 - against 280–4
- instantaneous death rate 193
- intention-to-treat (ITT) analysis 248–9, 250
- internal pilot studies 272

- internal reliability 203
 internal validity 209
 interquartile range 30, **33**
 calculation **31**
 interval scale 8, 9
 intervention group **18**
 intra-class correlation coefficient
 (ICC) 204–5, 213
- Kaplan–Meier (K-M) survival
 curve 185–7
 calculation procedure 186–7
 worked example **187, 188, 189, 192**
- kappa statistic 207–8
 calculation 207, 214–15
 limitations 208
- Kruskall–Wallis test 131
- laboratory experiments 11
- labour in water/epidural anaesthetic
 trial **259, 268**
- least-squares estimates 158
- leg ulcer trial(s) 119–21, 121–3, 124,
 127–8, 128, 129, 131, 132, 135, **196, 197**
- likelihood ratio (LR) 54
- Likert scale 221, **222**
- limits of agreement 211
- linear regression 150, 156–65, 176–7
 significance test for 158–62
 worked example **177**
 see also multiple regression
- linear regression equation 157
- linear relationship, in linear
 regression 158–9
- log hazard ratio 195
- log transformation 192, 279
- logistic model
 checking 173–4
 consequences 173
 with multiple variables 133, 170
- logistic regression 150, 169–74
 more than one independent
 variable 170–1
 one independent variable 169
 use in case–control studies 172
- logit transformation 169
- Logrank test 189–90
 calculation procedure 189–90
 worked example **188, 190**
- longitudinal studies *see* cohort
 studies
- lower quartile 30, **31**
- lung cancer studies 3, 17, 218
- McNemar’s test 138, 144
- Mann–Whitney *U* test 126, 129–30, 131,
 279
- matched pairs 11, 119
- matched-pairs case–control studies
 136–8, 234–5
- maximum likelihood method 169
- mean(s) 11, 28–9, 34
 calculation **28**
 confidence interval for 89–91
 difference between 93, 95, **114**
 confidence interval for 93, 122, **123**,
 127, **128**
 sample size calculation 274
 standard error for **87–8, 95, 114**
- measured data 6, 8
- measurements
 reliability of 202
 repeatability of 203–5
 variability of 39–41, 203, 204
- measures of dispersion/spread/
 variability 28, 30–3
- measures of location 28–30, 34
- measures of symmetry 38–9
- median 11, 29–30, **33, 34**
 calculation **29, 31**
- median survival time 190
 hazard ratio and 192
 worked example **190**
- medical literature, statistical knowledge
 required 2
- meta-analysis 254–5
- method comparison studies 210–12
- mobile phone/glioma study **233**
- mode 30
- model, regression equation as 157,
 164–5
- model-based probability 48
- multi-stage random sampling 220
- multiple comparisons 289–90
- multiple logistic regression
 equation 170–1
- multiple logistic regression model 133,
 170

- multiple regression 166–8, 279, 282
- multiple regression equation 166
- multiplication rule of probabilities 52
- mutually exclusive events 56–7

- neuroblastoma, children with **182**, 183
- nominal categorical data 6, 6
- non-inferiority trials 249, **250**
- non-insulin-dependent diabetes trial **251**
- non-linear relationship, correlation coefficient not to be used with 154
- non-parametric tests 138
 - factors affecting use 138
 - reasons for not using 139
 - see also* Mann–Whitney *U* test; Wilcoxon signed rank test
- non-randomised studies 224–7
 - pre-test/post-test studies 224–5
 - quasi-experimental designs 226
- Normal distribution 69–73, 316–17
 - data transformation for 192, 279
 - population parameters 70, 94
 - for comparing two groups 95, 114
 - probability distribution function 76
 - residuals for linear regression 160
- Normal probability plots 177–8
- ‘not significant’ notation 279, 286
- null hypothesis 100–2, 106
 - rejection/non-rejection of 106–8
- number needed to treat (NNT) **17**, 258–9
- numerical data 6, 8

- observational studies 217–40
 - confounding in 4–5, 236
 - contrasted with randomised controlled trials 5, 218
- occupational studies, cross-sectional studies in 224
- odds 19
- odds ratio (OR) 19–21, 24
 - in case–control studies 20, 233, 234
 - confidence interval for 239
 - in logistic regression 169, 172
 - confidence interval for **170**
- one-sided tests 113
- open questions 221, **222**
- ordered categorical data 6–7
 - ordinal data 6–7, 6
- out-of-hours patient satisfaction questionnaire **209**
- outcome measure, standard deviation 265
- outliers 29
 - checking in logistic regression 174
 - effect on correlation coefficient 154
 - effects on various measures 29, 30
 - in method comparison studies 212

- p*-value(s) 103–4
 - interpreting **107**, 110
 - one-sided 113
 - two-sided 112–13
- Paediatric Asthma Quality of Life Questionnaire (PAQLQ) **205**
- paired data, exact test for 144
- paired observations
 - comparison of two groups
 - for categorical outcomes 136–8
 - for continuous outcomes 119–25
- paired *t*-test 120, 121–3, 279
- parallel group randomised trial 250, 251
- parameters 64, 80
- pathology review (example) **207–8**
- patient consent (in clinical trials) 256
- patient consultation study **250**
- Pearson chi-square 132, 135
- Pearson correlation coefficient 156, 175
 - inappropriate use 205
- percentages, checking 24
- pie chart 22
- Poisson distribution 66–7
 - population parameters 66, 94, 95
 - probability distribution function 75–6
- Poisson random variable 66
- pooled estimate 101, 102
- population attributable risk 229
- population mean 81
 - confidence interval for 89
- population parameters 81, 157
 - least-squares estimates 158
- populations 80–1
- post-marketing surveillance 231
- postal questionnaires 222–3
 - response rates 223

- postnatal urinary incontinence study **88**, **93**, **102**
- postoperative fever duration (trial) **185**
- power of test/study 109, *110*, 264
- pragmatic trials 248–9
- pre-test/post-test studies 224–5
- predictive value of test 51–2
applications **54**, **55**
- pregnant women, metabolic rate study **284**, **285**, **286**, **287**
- presentation of data
graphs 42
tables 43
- prevalence 220, 270
worked example **270–1**, **271**
- probability
frequency-based 46–8
model-based 48
subjective 48–9
types 46–9
- probability distribution 64
examples 65
- probability distribution function(s) 64
Binomial distribution 75
Normal distribution 76
Poisson distribution 75–6
- prolactin concentration study **74–5**, **95–6**
- proportional hazards model 194–7
- proportion(s) 14, **17**
confidence interval for 91–2, 95, **95–6**
difference between 93, 95, *114*
confidence interval for 93, 133, 144
sample size calculation 273
standard error for **88**, 95, *114*, 133, 144
standard error for 85–6, 94, 270
- prospective studies *see* cohort studies
- pulse rate
factors affecting 41
variability **39**, 40–1, 40, **203**
- qualitative data 6–8, 6
describing 14–21
displaying 21–3
- quantitative data 6, 8
describing 28–34
displaying 34–9, 42–3
- quartiles 30–1
calculation **31**
- quasi-experimental studies 226
disadvantages 226
example **226–7**
- questionnaires 10, 221–2
design 221–2
measure of internal consistency 209, 213
purpose 221
types of questions 221–2
- quota samples 223
- random numbers table(s) 84, 220, 245, 318
- random sample 81, 220
- random variable 64
- random variation 41
- randomisation 242–3
balanced/blocked/restricted 245–6
how to do 246–7
methods 244–6
minimisation method 246
reasons for 243
simple 244–5
stratified 246
- randomised controlled trial(s)
241–60
'blind' assessment 248
cluster designs 252–3
contrasted with observational studies 5, 218
cross-over designs 251–2
design features 247–50, 256–7
checklist 257
in protocol 255
design options 250–4
double-blind trials 10, 248
equivalence trials 249–50
explanatory trials 248
factorial designs 247, 253–4
follow-up 248
intention-to-treat analysis 248–9, 250
meta-analysis of 254–5
methods of randomisation 244–6
need for control group 247
non-inferiority trials 249, **250**
'number needed to' as measure 258–9

- parallel designs 250, 251
- patient entry criteria 243–4, 247, 255, 260
- personnel and their roles 255
- pragmatic trials 248–9
- presentation of data and report 257–8
- protocol for 243, 255–6
- size 256, 264
- statistical analysis of data 256, 257–8
- subject withdrawals 271–2
- treatment choice 247–8
- range 30
 - calculation **31**
- ranks 7–8
- rate(s) 14, **15**, 219
 - calculation 219
 - confidence interval(s) for 92
 - standard errors for 85–6, **87**, 94
- ratio 14
 - see also* hazard ratio; odds ratio; risk ratio
- ratio scale 8–9
- reference interval 33, 74
- reference range 73–4
 - examples **74–5**
- regression
 - compared with correlation 150, 165–6
 - see also* linear regression; logistic regression
- regression coefficient(s)
 - Cox model 195
 - linear regression 157
 - logistic regression 169
 - multiple regression 166
- regression line 156–8
- regression model, prediction using 164–5
- regression to mean 281–3
- relative frequency histograms 35, 68
- relative (receiver) operating characteristic (ROC) curve
 - 57–9
 - analysis 59
 - area under curve (AUC) 59
 - example 58
- relative risk (RR) **17**, **18**, 24
 - approximate 19, 20
 - in cohort study 227
 - confidence interval for 238–9
 - estimation in case–control studies 172, 233
 - meaning of term 191, 227
 - see also* hazard ratio
 - reliability 202–3
 - repeatability 203–5
 - repeated measures 284–7
 - invalid approaches 286–7
 - valid approaches 287
 - representative sample 10
 - research hypothesis 100
 - residuals
 - linear regression 158–9
 - independence 161–2
 - non-randomness **162**, 163
 - plot against fitted values 159, 160
 - plot against Normal ordinates 160, 161, 178
 - logistic regression 174
 - resting carotid pulse rate, variability **39**, 40, 281
 - restricted randomisation techniques 245–6
 - retrospective studies *see* case–control studies
 - risk **14**, **17**, 218–19
 - risk ratio (RR) **17**
 - Royal Statistical Society, logo 5
 - running speed, prediction from pulse rate **164**
- safety advice, telephone survey **207**
- sample choice 10
- sample mean(s) 82, 100
 - standard deviation **82**
- sample size calculations 9–10, 261–75
 - binary data 264, 265, 268–71
 - continuous data 264, 265, 267
 - effect size 265–6
 - reasons for 262
- sample statistics 81
- samples 81–2
- sampling frame 81
- scatter plots 37, 38, 152
 - with different correlations 153
 - regression line fitted 157, 163

- residuals from linear regression 159, 160, 163
- selection bias 223, **224**
- sensitivity of test 49–51
 - example **57**
 - ROC curves 58
- significance level 105, 106, 107
- significance test of correlation 155
 - assumptions underlying 156, 165–6
- significance test of regression 158, 165
 - assumptions underlying 158–64, 165–6
- simple randomisation 244–5
- Simpson's paradox 236
 - illustrative example **236**, 237
- skewed distributions 38–9
- slate-workers study **228**, 229, **230**
- smoking cessation study **18**, 19
- smoking-effect studies 3, 17, 230
- Spearman rank correlation
 - coefficient 156, 165, 176
- special care baby unit study 15, **15**, 16, 21, 22, 23, **28**, **29**, **31**, **32**, 35, 36, 37, 38, 38, 68
- specificity of test 49–51
 - example **57**
 - ROC curves 58
- spirometers, agreement between **211**, **212**
- spread, measures of 28, 30–3
- standard deviation 31, 33, **33**, 87
 - calculation **32–3**
 - compared with standard error 87, 94
 - of sample means **82**
- standard error(s) 82–4, 87
 - compared with standard deviation 87, 94
 - for difference in means **87–8**, 95, 121, 123, 127, 128
 - for difference in proportions **88**, 95, 133, 144
 - of differences 87–8
 - of mean (SEM) 82, 94
 - properties **83–4**
 - of proportions and rates 85–6, 94, 270
- Standard Normal distribution 70
 - area under 71, 72, 316–17
 - probability distribution function 76
- standardised effect size 267
- statistical analysis 11
 - factors affecting choice of method 118
 - pitfalls encountered 277–90
- statistical calculations, validity 3
- statistical inference
 - comparison of independent groups
 - categorical outcomes 132–6
 - continuous outcomes 125–31
 - comparison of paired observations
 - categorical outcomes 136–8
 - continuous outcomes 119–25
 - hypothesis testing 105–8
- statistical significance
 - distinction from clinical importance 111, 288
 - meaning of term 106, 107, 110, 123, 124, 128, 279
 - sample size and 9–10
- statistical tests, factors affecting choice of test 118
- statistics, reasons for use 3
- stratified randomisation 246
- stroke/CT scan study **224–5**
- Student's *t*-distribution 121, 140–1, 155
- Student's *t*-statistic, *m* 141
- study hypothesis 100
- study size 256, 263–7
- subgroup analysis 289
- subject withdrawals (from clinical trials) 271–2
- subjective probability 48–9
- subsidiary hypotheses 289
- suicide study **235**
- summary statistics 11
- superiority of treatments, equivalence trials 249–50
- survival analysis 181–200
 - interpreting results (in literature) 197–8
- survival time studies 182–4, 263
- symmetry (of distribution of data), measures of 38–9
- systematic allocation method 243
- systematic random sampling 220
- t*-tests 120, 121–3, 125–8
 - inappropriate use 278–80
- tabular presentation of data 43
- test–retest reliability 203

- test size 109, 264
- test statistic, general formula 106
- testicular cancer study 137–8, 144
- time-to-event data 182–4
 - ‘calendar time’ compared with ‘patient time’ 182–4
 - modelling 193–7
- two-sample *t*-tests
 - independent samples 125–8
 - paired samples 120, 121–3
- two-sided tests 112–13
- Type I error 107, 109, 110, 174
- Type I error rate 109, 264
- Type II error 109, 110
- Type II error rate 109, 264

- ulcerative colitis trial **185**, 186, **190**
- unmatched case–control studies 232–3
- unpaired data
 - exact test for 136, 141–2
 - see also*
 - independent groups of data/observations
- upper quartile 30, **31**

- validity 209
- variability
 - of biological data 3
 - measures 28, 30–3
- variance 32
 - calculation **32–3**
- variation, coefficient of 203
- visual analogue score (VAS) 222, **222**
- volunteers, in cross-sectional studies 223

- weighted kappa 208
- Wilcoxon (matched pairs) signed rank test 120, 123–5
- Wilcoxon *W* statistic 129, 131
- within-subject standard deviation **39**, 203, 213
- within-subject variability 39–41
- within-subject variance 213

- Yates’ continuity correction 132, 135, 136

- z*-test 103, **105**, 140

